The multi-center clinical study of etimicin injection against acute bacterial infections

Jian Zhou,Deying Tian,Daofeng Yang,Jingchuan Zheng,Lixian He,Erzhang Chen,Liyun Li,Xiaying Zhou,Xiaoju Lu,Yagang Chen,Chunyan Yu,Xuehua Chen,Bijie Hu,Zhaolong Cao,Zongming Zhao,Jing Huang,Rujia Yu
DOI: https://doi.org/10.3969/j.issn.1001-8689.2000.z1.001
2000-01-01
Abstract:To evaluate the efficacy and safety of etimicin injection, 2212 patients with acute bacterial infections in respiratory tract, urinary tract, digestive tract, and other infections were treated with the drug in an opened trial. Etimicin were administered single (100mg, q12h or 200mg, qd) or association (combinated with other antimicrobial agents sanctioned by government) for 5~10 days. The results showed that the total cure rate, effective rate, bacterial clearance rate and adverse reaction rate were 61.2%, 91.8%, 91.7%, 4.33% respectively for single administered and 48.5%, 85.1%, 88.6%, 4.4% respectively for association administered. The mostly adverse reactions were generally mild and well tolerated. Only 14 patients occur hypoacusis (0.73%); 7 patients occur hepatic or renal function disorders (0.37%). The results indicated that etimicin injection is an effective and safe drug with lower toxity, and may contribute to treat the patients with serious bacterial infections combinated with other antibiotics.
What problem does this paper attempt to address?